15 research outputs found
Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
YesRecent clinical trials of the hypoglycaemic sodium-glucose co-transporter-2 (SGLT2) inhibitors, which inhibit renal glucose reabsorption, have reported beneficial cardiovascular outcomes. Whether SGLT2 inhibitors directly affect cardiovascular tissues, however, remains unclear. We have previously reported that the SGLT2 inhibitor canagliflozin activates AMP-activated protein kinase (AMPK) in immortalised cell lines and murine hepatocytes. As AMPK has anti-inflammatory actions in vascular cells, we examined whether SGLT2 inhibitors attenuated inflammatory signalling in cultured human endothelial cells. Incubation with clinically-relevant concentrations of canagliflozin, but not empagliflozin or dapagliflozin activated AMPK and inhibited IL-1β-stimulated adhesion of pro-monocytic U937 cells and secretion of IL-6 and monocyte chemoattractant protein-1 (MCP-1). Inhibition of MCP-1 secretion was attenuated by expression of dominant-negative AMPK and was mimicked by the direct AMPK activator, A769662. Stimulation of cells with either canagliflozin or A769662 had no effect on IL-1β-stimulated cell surface levels of adhesion molecules or nuclear factor-κB signalling. Despite these identical effects of canagliflozin and A769662, IL-1β-stimulated IL-6/MCP-1 mRNA was inhibited by canagliflozin, but not A769662, whereas IL-1β-stimulated c-jun N-terminal kinase phosphorylation was inhibited by A769662, but not canagliflozin. These data indicate that clinically-relevant canagliflozin concentrations directly inhibit endothelial pro-inflammatory chemokine/cytokine secretion by AMPK-dependent and -independent mechanisms without affecting early IL-1β signalling.Project Grant (PG/13/82/30483 to IPS and TMP) and PhD studentships (FS/16/55/32731 and FS/14/61/31284 to DB and AS) from the British Heart Foundation and an equipment grant (BDA11/0004309 to IPS and TMP) from Diabetes UK. OJK was supported by a Scholarship from the Iraqi Ministry of Higher Education and Scientific Research. TAA was supported by a Libyan Ministry of Education PhD Studentship
The use of 3D printed microporous-strut polycaprolactone scaffolds for targeted local delivery of chemotherapeutic agent for breast cancer application
Local recurrent cancer remains a challenge for breast cancer patients receiving implants after mastectomy or lumpectomy. The use of radiotherapy and/or systemic administration of chemotherapeutic agents post-surgery can be beneficial yet they also kill healthy cells and introduce systemic side effects. In this study, a new method was introduced to utilize 3D printed microporous polycaprolactone (PCL) scaffolds as a multifunctional device—an implant and a drug delivery vehicle for targeted local delivery. Their microporous structure was characterized by scanning electron microscopy (SEM) and atomic force microscopy (AFM). The dependence of release profiles of Doxorubicin (DOX) loaded scaffolds on pH and ionic strength of the environment was demonstrated. Lastly, their chemotherapeutic effect was characterized by in vitro. Overall, the results demonstrated the utility of the microporosity and surface charge of PCL scaffolds to immobilize DOX for local, targeted drug delivery